Major structural proteins of type 1 and type 3 Klebsiella fimbriae are effective protein carriers and immunogens in conjugates as revealed from their immunochemical characterization
- PMID: 15949924
- DOI: 10.1016/j.femsim.2005.04.005
Major structural proteins of type 1 and type 3 Klebsiella fimbriae are effective protein carriers and immunogens in conjugates as revealed from their immunochemical characterization
Abstract
Fimbriae are filamentous structures present on the cell surface of many bacteria, including genus Klebsiella. The use of fimbriae as protein carriers in conjugates may allow to formulate effective multivalent vaccines and suitable diagnostics. However, the evidences have been reported that fimbriae may enhance the inflammatory response. This prompted us to examine the degree of cytokine induction by the type 1 and type 3 Klebsiella fimbriae and their conjugates. Fimbriae were assessed as carrier proteins for Escherichia coli K12 endotoxin core oligosaccharide. MALDI-MS revealed the molecular mass of fimbrial monomer major protein, which was 15,847 Da for type 1 and 18,574 Da for type 3 fimbriae of Klebsiella. These two types of fimbriae were moderate inductors of IL-6 and interferon and almost inactive with regard to the stimulation of TNF when tested in human whole blood assay. Coupling of fimbriae with E. coli K12 core oligosaccharide gave immunogenic conjugates with respect to a saccharide ligand and protein carrier, although only 10% of the pilin monomers possessed the attached oligosaccharide. Rabbit antiserum reacted with a broad spectrum of lipopolysaccharides, as measured by ELISA and immunoblotting assays. The antibodies against glycoconjugates were bactericidal for the wild, S-type bacteria of some species. Regarding the induction of cytokines by conjugates only the TNF level was noticeably elevated. These results prompt for the practical use of fimbriae, as effective protein carriers for conjugates to obtain broad-spectrum antisera for diagnostic applications.
Similar articles
-
Structure and characterization of AgfB from Salmonella enteritidis thin aggregative fimbriae.J Mol Biol. 2001 Aug 24;311(4):735-49. doi: 10.1006/jmbi.2001.4876. J Mol Biol. 2001. PMID: 11518527
-
A comparative study of the type-3 fimbriae of Klebsiella species.J Med Microbiol. 1985 Oct;20(2):203-14. doi: 10.1099/00222615-20-2-203. J Med Microbiol. 1985. PMID: 2864453
-
MrkF is a component of type 3 fimbriae in Klebsiella pneumoniae.Res Microbiol. 2009 Jan-Feb;160(1):71-9. doi: 10.1016/j.resmic.2008.10.009. Epub 2008 Nov 8. Res Microbiol. 2009. PMID: 19028568
-
[Fimbriae as a pathologic factor of bacteria and a carrier in conjugate vaccines].Postepy Hig Med Dosw. 2000;54(6):727-47. Postepy Hig Med Dosw. 2000. PMID: 11227372 Review. Polish.
-
Combining sites of bacterial fimbriae.Curr Opin Struct Biol. 2007 Oct;17(5):506-12. doi: 10.1016/j.sbi.2007.06.011. Epub 2007 Aug 23. Curr Opin Struct Biol. 2007. PMID: 17719218 Review.
Cited by
-
KbvR mutant of Klebsiella pneumoniae affects the synthesis of type 1 fimbriae and provides protection to mice as a live attenuated vaccine.Vet Res. 2022 Nov 26;53(1):97. doi: 10.1186/s13567-022-01116-y. Vet Res. 2022. PMID: 36435858 Free PMC article.
-
Progress towards the development of Klebsiella vaccines.Expert Rev Vaccines. 2019 Jul;18(7):681-691. doi: 10.1080/14760584.2019.1635460. Epub 2019 Jun 28. Expert Rev Vaccines. 2019. PMID: 31250679 Free PMC article. Review.
-
Prophylaxis and Treatment against Klebsiella pneumoniae: Current Insights on This Emerging Anti-Microbial Resistant Global Threat.Int J Mol Sci. 2021 Apr 14;22(8):4042. doi: 10.3390/ijms22084042. Int J Mol Sci. 2021. PMID: 33919847 Free PMC article. Review.
-
Current Stage in the Development of Klebsiella pneumoniae Vaccines.Infect Dis Ther. 2021 Dec;10(4):2157-2175. doi: 10.1007/s40121-021-00533-4. Epub 2021 Sep 2. Infect Dis Ther. 2021. PMID: 34476772 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources